A detailed history of China Universal Asset Management Co., Ltd. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 27,535 shares of DNLI stock, worth $591,727. This represents 0.09% of its overall portfolio holdings.

Number of Shares
27,535
Previous 16,753 64.36%
Holding current value
$591,727
Previous $389,000 106.17%
% of portfolio
0.09%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$20.96 - $31.05 $225,990 - $334,781
10,782 Added 64.36%
27,535 $802,000
Q2 2024

Jul 19, 2024

SELL
$14.96 - $23.22 $149,121 - $231,456
-9,968 Reduced 37.3%
16,753 $389,000
Q1 2024

Apr 29, 2024

BUY
$15.83 - $23.35 $170,014 - $250,779
10,740 Added 67.2%
26,721 $548,000
Q4 2023

May 21, 2024

SELL
$16.2 - $23.18 $173,988 - $248,953
-10,740 Reduced 40.19%
15,981 $342,000
Q4 2023

Jan 23, 2024

BUY
$16.2 - $23.18 $201,771 - $288,706
12,455 Added 353.23%
15,981 $343,000
Q3 2023

May 21, 2024

BUY
$20.63 - $30.17 $35,731 - $52,254
1,732 Added 96.54%
3,526 $72,000
Q3 2023

Oct 30, 2023

BUY
$20.63 - $30.17 $35,731 - $52,254
1,732 Added 96.54%
3,526 $73,000
Q2 2023

May 21, 2024

SELL
$23.37 - $32.96 $1,332 - $1,878
-57 Reduced 3.08%
1,794 $52,000
Q2 2023

Jul 27, 2023

SELL
$23.37 - $32.96 $1,332 - $1,878
-57 Reduced 3.08%
1,794 $53,000
Q1 2023

May 21, 2024

BUY
$21.91 - $32.67 $10,319 - $15,387
471 Added 34.13%
1,851 $42,000
Q1 2023

Apr 27, 2023

BUY
$21.91 - $32.67 $10,319 - $15,387
471 Added 34.13%
1,851 $43,000
Q4 2022

May 21, 2024

SELL
$26.28 - $33.92 $665,961 - $859,566
-25,341 Reduced 94.84%
1,380 $38,000
Q4 2022

Jan 31, 2023

BUY
$26.28 - $33.92 $5,913 - $7,632
225 Added 19.48%
1,380 $38,000
Q3 2022

Oct 21, 2022

BUY
$25.97 - $38.53 $29,995 - $44,502
1,155 New
1,155 $35,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.